Nocturnal enuresis (NE) is the involuntary voiding of urine during sleep in the absence of physical disease in children above the age of 5 years. The major causes of NE are urinary bladder dysfunction and nocturnal polyuria (NP). In NP, reduction in the nocturnal level of arginine vasopressin (AVP) leads to a high urine output at night. Desmopressin acetate (DDAVP) is commonly used to treat NP, but not all patients respond to DDAVP. Therefore, a new objective biomarker to reflect AVP secretion during sleep is warranted, to select patients with NE for treatment with DDAVP.Aquaporin 2 (AQP2) is an AVP‐sensitive water channel that mediates transmembrane water transport in the collecting ducts. AQP2 is excreted into the urine, and its excretion increases in response to AVP. Therefore, urinary excretion of AQP2 is proposed to be a biomarker of the responsiveness of the collecting duct to AVP.To investigate whether AQP2 level in morning urine could be used as an objective biomarker of NP, we measured urinary AQP2/creatinine (AQP2/Cr) in 34 NE patients (23 male, 11 female; mean age, 9.6 ± 2.1 years), of whom 28 had NP. NP was defined according to the following Japanese criteria: nocturnal urine volume >0.9 mL/kg/h of sleep or
Pediatrics International – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud